Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PolyPEPI1018 and Atezolizumab in Relapsed/Refractory MSS Metastatic Colorectal Cancer
NCT05243862Phase 2Completed
- Sponsor
- Treos Bio
- Start
- Jun 2022
- Primary completion
- Jul 2024
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PolyPEPI1018 in colorectal cancer (CRC), sponsored by Treos Bio. Primary endpoints: Incidence and Severity Treatment Related Adverse Events at 7.5 months, Clinical Laboratory Safety at 12 months and 1 more. Started Jun 2022; status: completed.
02
Drugs
PolyPEPI1018
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05243862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05243862.